Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer.

Next Previous
Trial Profile

A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Spinnaker
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 23 Jun 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
    • 11 Oct 2010 As a result of the primary endpoint of the trial not being met, Lilly will not submit marketing authorization applications for pemetrexed in this indication with either the US FDA or the EMA in Europe, as reported in an Eli Lilly media release.
    • 11 Oct 2010 Primary endpoint 'Overall survival' has not been met, as reported in a media release from Eli Lilly.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top